Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbffa3b81b3b862dc7220b5648f5f745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70589 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate |
2019-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b63a36272c9e55a5a1391b8afdd973c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c94e613588cda4782e7aec08266fa4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de2bdc0bb598123891d2d67cdcccc098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fedd45a02fb4e6e266f1814cf186d6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01954ae742c684410f76b3f8669f4579 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee14b2285c507a9f66382a42ec9dc1d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b03be23a6d24fe13c246c143c427bf4 |
publicationDate |
2021-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20210050278-A |
titleOfInvention |
Biomarkers for predicting prognosis after immunotherapy of cancer |
abstract |
The present invention relates to a biomarker for selecting a patient for which the occurrence of accelerated tumor progression (HPD) is predicted after treatment with an immunological anticancer drug (PD-1/PD-L1). The composition of the present invention contains two selected markers (CCR7-CD45RA-, TIGIT+), and is immune to non-small cell lung cancer patients by predicting in advance the occurrence of HPD before using an immuno-anticancer agent for cancer patients, especially non-small cell lung cancer patients. Since it is possible to decide whether to use an anticancer drug, it is expected that the life expectancy can be extended by predicting a group of patients who will show a prognosis such as accelerated progression of cancer after treatment with an immune anticancer drug early and receiving customized treatment. |
priorityDate |
2019-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |